Logo image of HRMY

HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock - Currency: USD

32.11  +0.08 (+0.25%)

After market: 32.11 0 (0%)

Fundamental Rating

8

Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 195 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. With these ratings, HRMY could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

HRMY had positive earnings in the past year.
In the past year HRMY had a positive cash flow from operations.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of HRMY (14.49%) is better than 96.41% of its industry peers.
With an excellent Return On Equity value of 21.22%, HRMY belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
HRMY's Return On Invested Capital of 18.05% is amongst the best of the industry. HRMY outperforms 94.36% of its industry peers.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.26%. This is above the industry average of 14.87%.
Industry RankSector Rank
ROA 14.49%
ROE 21.22%
ROIC 18.05%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.56%
ROE(5y)9.52%
ROIC(3y)18.26%
ROIC(5y)15.28%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

HRMY's Profit Margin of 20.54% is amongst the best of the industry. HRMY outperforms 93.85% of its industry peers.
In the last couple of years the Profit Margin of HRMY has grown nicely.
HRMY has a Operating Margin of 28.46%. This is amongst the best in the industry. HRMY outperforms 94.36% of its industry peers.
In the last couple of years the Operating Margin of HRMY has declined.
HRMY's Gross Margin of 78.34% is amongst the best of the industry. HRMY outperforms 86.67% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.46%
PM (TTM) 20.54%
GM 78.34%
OM growth 3Y-2.3%
OM growth 5YN/A
PM growth 3Y21.43%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HRMY is creating value.
Compared to 1 year ago, HRMY has about the same amount of shares outstanding.
HRMY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for HRMY has been reduced compared to a year ago.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

HRMY has an Altman-Z score of 5.26. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HRMY (5.26) is better than 82.05% of its industry peers.
HRMY has a debt to FCF ratio of 0.79. This is a very positive value and a sign of high solvency as it would only need 0.79 years to pay back of all of its debts.
HRMY has a Debt to FCF ratio of 0.79. This is amongst the best in the industry. HRMY outperforms 96.41% of its industry peers.
HRMY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
HRMY's Debt to Equity ratio of 0.22 is in line compared to the rest of the industry. HRMY outperforms 43.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 0.79
Altman-Z 5.26
ROIC/WACC1.83
WACC9.86%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.67 indicates that HRMY has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.67, HRMY is doing good in the industry, outperforming 60.51% of the companies in the same industry.
HRMY has a Quick Ratio of 3.64. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a better Quick ratio (3.64) than 63.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.64
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

8

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.82% over the past year.
The Earnings Per Share has been growing by 44.61% on average over the past years. This is a very strong growth
The Revenue has grown by 20.62% in the past year. This is a very strong growth!
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%

3.2 Future

The Earnings Per Share is expected to grow by 35.76% on average over the next years. This is a very strong growth
HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.23% yearly.
EPS Next Y33.8%
EPS Next 2Y27.83%
EPS Next 3Y28.9%
EPS Next 5Y35.76%
Revenue Next Year17.85%
Revenue Next 2Y17.93%
Revenue Next 3Y18.6%
Revenue Next 5Y18.23%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.26, which indicates a correct valuation of HRMY.
Compared to the rest of the industry, the Price/Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 88.21% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of HRMY to the average of the S&P500 Index (27.28), we can say HRMY is valued rather cheaply.
With a Price/Forward Earnings ratio of 7.83, the valuation of HRMY can be described as very cheap.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 88.21% of the companies are valued more expensively.
HRMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 12.26
Fwd PE 7.83
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

HRMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HRMY is cheaper than 93.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HRMY is valued cheaply inside the industry as 92.82% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.32
EV/EBITDA 6.32
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
HRMY's earnings are expected to grow with 28.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y27.83%
EPS Next 3Y28.9%

0

5. Dividend

5.1 Amount

HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (7/2/2025, 8:00:02 PM)

After market: 32.11 0 (0%)

32.11

+0.08 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners80.19%
Inst Owner Change-2.03%
Ins Owners0.56%
Ins Owner Change0.05%
Market Cap1.84B
Analysts80
Price Target52.02 (62.01%)
Short Float %8.5%
Short Ratio5.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.9%
Min EPS beat(2)12.8%
Max EPS beat(2)31%
EPS beat(4)4
Avg EPS beat(4)117.47%
Min EPS beat(4)12.8%
Max EPS beat(4)409.61%
EPS beat(8)6
Avg EPS beat(8)58.83%
EPS beat(12)9
Avg EPS beat(12)123.33%
EPS beat(16)12
Avg EPS beat(16)89.38%
Revenue beat(2)0
Avg Revenue beat(2)-1.4%
Min Revenue beat(2)-1.83%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-1.83%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-1.39%
Revenue beat(12)4
Avg Revenue beat(12)-0.54%
Revenue beat(16)5
Avg Revenue beat(16)-0.52%
PT rev (1m)0.22%
PT rev (3m)-1.71%
EPS NQ rev (1m)-10.2%
EPS NQ rev (3m)-7.64%
EPS NY rev (1m)2.39%
EPS NY rev (3m)6.9%
Revenue NQ rev (1m)-0.42%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE 12.26
Fwd PE 7.83
P/S 2.48
P/FCF 8.32
P/OCF 8.27
P/B 2.56
P/tB 3
EV/EBITDA 6.32
EPS(TTM)2.62
EY8.16%
EPS(NY)4.1
Fwd EY12.77%
FCF(TTM)3.86
FCFY12.03%
OCF(TTM)3.88
OCFY12.09%
SpS12.97
BVpS12.56
TBVpS10.69
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.49%
ROE 21.22%
ROCE 24.06%
ROIC 18.05%
ROICexc 42.52%
ROICexgc 59.55%
OM 28.46%
PM (TTM) 20.54%
GM 78.34%
FCFM 29.77%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.56%
ROE(5y)9.52%
ROIC(3y)18.26%
ROIC(5y)15.28%
ROICexc(3y)40.77%
ROICexc(5y)37.46%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexcg growth 3Y-76.77%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.85%
ROICexc growth 5YN/A
OM growth 3Y-2.3%
OM growth 5YN/A
PM growth 3Y21.43%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 0.79
Debt/EBITDA 0.67
Cap/Depr 5.3%
Cap/Sales 0.17%
Interest Coverage 12.76
Cash Conversion 94.51%
Profit Quality 144.92%
Current Ratio 3.67
Quick Ratio 3.64
Altman-Z 5.26
F-Score5
WACC9.86%
ROIC/WACC1.83
Cap/Depr(3y)59.28%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.98%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
EPS Next Y33.8%
EPS Next 2Y27.83%
EPS Next 3Y28.9%
EPS Next 5Y35.76%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%
Revenue Next Year17.85%
Revenue Next 2Y17.93%
Revenue Next 3Y18.6%
Revenue Next 5Y18.23%
EBIT growth 1Y4.13%
EBIT growth 3Y29.72%
EBIT growth 5YN/A
EBIT Next Year52.59%
EBIT Next 3Y31.55%
EBIT Next 5Y25.65%
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.96%
OCF growth 3Y30.67%
OCF growth 5YN/A